

# Astragalus IV Undermines Multi-Drug Resistance and Glycolysis of MDA-MB-231/ADR Cell Line by Depressing hsa\_circ\_0001982-miR-206/miR-613 Axis

Hongchang Li<sup>1,\*</sup>Zhihua Xia<sup>2,\*</sup>Limin Liu<sup>3,\*</sup>Gaofeng Pan<sup>1</sup>Junbin Ding<sup>1</sup>Jiazhe Liu<sup>1</sup>Jie Kang<sup>1</sup>Jindong Li<sup>1</sup>Daowen Jiang<sup>1</sup>Weiyang Liu<sup>1</sup>

<sup>1</sup>Department of General Surgery, Institute of Fudan-Minhang Academic Health System, Minhang Hospital, Fudan University, Shanghai, 201100, People's Republic of China; <sup>2</sup>Department of General Surgery, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, People's Republic of China; <sup>3</sup>Department of Medical Rehabilitation, Heze Domestic Professional College, Heze, 274300, Shandong, People's Republic of China

\*These authors contributed equally to this work

**Background:** Allowing for the power of astragalus in improving cancer patients' response to chemotherapy, we endeavored to clarify if hsa\_circ\_0001982-centered miRNA axes participated in the impact of astragaloside IV on multi-drug resistance (MDR) of triple-negative breast cancer (TNBC).

**Methods:** TNBC patients were recruited into an Astragalus detoxification decoction (ADD) treatment group (N=62) and a non-ADD treatment group (N=78), according to whether they consumed ADD after chemotherapy or not. Furthermore, drug resistance of the MDA-MB-231/ADR cell line in response to gemcitabine (GEM), adriamycin (ADM), oxaliplatin (OXA), and cisplatin (DDP) was evaluated, and glycolytic potential of MDA-MB-231/ADR cells was determined after astragaloside IV treatment or si-hsa\_circ\_0001982/miR-206 inhibitor/miR-613 inhibitor transfection.

**Results:** TNBC patients receiving ADD adjuvant therapy after chemotherapy, with decreased serum level of hsa\_circ\_0001982 and increased serum level of miR-206/miR-613 as relative to non-ADD treatment group ( $P<0.05$ ), were less likely to relapse than TNBC population not undergoing ADD treatment ( $P<0.05$ ). In addition, GEM/ADM/OXA/DDP-resistance and glycolysis of MDA-MB-231/ADR cell line were debilitated after exposure to astragaloside IV or transfection by si-hsa\_circ\_0001982 ( $P<0.05$ ). Nonetheless, miR-206/miR-613 inhibitor transfection reversed inhibitory effects of si-hsa\_circ\_0001982 and astragaloside IV on glycolysis and MDR of MDA-MB-231/ADR cell line ( $P<0.05$ ).

**Conclusion:** Astragaloside IV undermined MDR and glycolysis of MDA-MB-231/ADR cell line by blocking hsa\_circ\_0001982-miR-206/miR-613 axis.

**Keywords:** triple-negative breast cancer, astragaloside IV, hsa\_circ\_0001982, miR-206, miR-613, multi-drug resistance, glycolysis

## Introduction

Triple-negative breast cancer (TNBC), primarily occurring among premenopausal women, is a breast cancer (BC) subtype without estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).<sup>1</sup> In the light of epidemiological data, patients of TNBC comprises approximately 16% of all BC cases.<sup>2</sup> Although multiple chemotherapy strategies, which appear superior in shrinking tumor lesions, have been formulated to avert TNBC recurrence, prognosis of TNBC is not so desirable as anticipated.<sup>3</sup> Scholars attribute this gap partly to the

Correspondence: Weiyang Liu; Daowen Jiang  
Department of General Surgery, Institute of Fudan-Minhang Academic Health System, Minhang Hospital, Fudan University, No. 170 Xinsong Road, Shanghai, 201100, People's Republic of China  
Email: wylu13@163.com; 18918169215@189.cn

development of multidrug resistance (MDR), which is defined as that tumor cells tend to become resistant against a range of drugs with completely discrepant structures, functions, and action modes.<sup>4</sup> It seems that, therefore, elucidating etiology of MDR is paramount to improve post-chemotherapy outcome of TNBC.

It is increasingly recognized that circRNAs, featured by closed loop without 5'-cap or 3'-poly(A) tail, participates in modulating carcinogenesis, including lung cancer, gastric cancer, colorectal cancer,<sup>5</sup> and BC.<sup>6</sup> For instance, Li et al<sup>7</sup> and Tang et al,<sup>8</sup> respectively, expected that hsa\_circ\_0001982, a circRNA derived from *RNF111*,<sup>9</sup> served as an oncogene in gastric cancer and BC. However, the implication of hsa\_circ\_0001982 in specific BC subtypes (eg, TNBC) has been inconclusive. Of note, the competing endogenous RNA (ceRNA) hypothesis held that circRNAs could sequester cancer-promoting/inhibiting miRNAs, thereby depressing expression of the miRNAs and ultimately manipulating oncogenesis.<sup>10</sup> For example, circHIPK3 was speculated to postpone metastasis of bladder cancer by sponging miR-558.<sup>11</sup> As estimated by the Encyclopedia of RNA Interactomes (ENCORI) online database,<sup>12</sup> hsa\_circ\_0001982 revealed vast potential to sponge miR-206 and miR-613, both of which antagonized deterioration of TNBC,<sup>13,14</sup> so it was conjectured that hsa\_circ\_0001982 might involve in TNBC pathogenesis by regulating miR-206 and miR-613. Nevertheless, this assumption has not yet been proved by any convincing research.

Additionally, traditional Chinese medicines (TCMs) have been renowned in terms of depressing tumor growth, reducing toxicity of chemoradiotherapy, and strengthening immunity.<sup>15,16</sup> For example, extract of *Coptis chinensis* markedly curbed multiplication of MCF-7 cells by raising levels of TNF- $\alpha$  and IFN- $\beta$ ,<sup>17</sup> while aqueous extract of *Brucea javanica* played obvious roles in facilitating apoptosis of non-small cell lung cancer cells, hepatocellular carcinoma cells, BC cells, and oesophageal squamous cell carcinoma cells.<sup>18</sup> Astragaloside IV, an active ingredient of astragalus root (*Radix Astragali*), was also reported to weaken MDR of drug-resistant tumor cells (eg, Bel-7402/FU),<sup>19</sup> nonetheless, whether astragaloside IV prevented MDR development in TNBC and if the underlying molecular explanations was relevant to circRNA/miRNA axis remained elusive.

Hence, this investigation was intended to clarify the association of hsa\_circ\_0001982-miR-206/miR-613 axis with impacts of astragaloside IV on MDR of TNBC,

offering clues to whether astragalus was clinically beneficial to TNBC treatment.

## Materials and Methods

### Collection of TNBC Patients

One hundred and forty pathologically-confirmed TNBC patients, who survived for >3 years after surgery, were recruited in Minhang Hospital affiliated to Fudan University from November 2012 to November 2017. The TNBC cases were incorporated into 1) an Astragalus detoxification decoction (ADD) treatment group (N=62) and 2) a non-ADD treatment group (N=78), according to whether they consumed ADD after chemotherapy or not. And TNBC patients were included if: 1) they were female primary BC cases clinically staged as II/III; 2) they experienced full cycle of conventional chemotherapy; and 3) they received comprehensive physical examinations, including color ultrasound, CT, whole body bone scan, and tumor biomarkers detection. They would be excluded when: 1) their tumor lesions were excised through non-standard surgery; 2) their chemotherapy was terminated halfway; 3) they were complicated by severe disorders in the heart, kidney, liver, and endocrine system; 4) they were mentally disordered; 5) they simultaneously participated in other clinical trials; and 6) they refused to take medicines as prescribed, and their efficacy was hard to estimate. All participants signed informed consent before collection of their blood samples. This program was conducted in accordance with the Declaration of Helsinki, and approvals were obtained from Minhang Hospital affiliated to Fudan University and the ethics committee of Minhang Hospital affiliated to Fudan University.

### Treatment Regimen for TNBC Patients

TNBC patients of the non-ADD treatment group all performed surgery and postoperative chemotherapy. In addition to the treatments, TNBC patients of the ADD treatment group were also orally given ADD twice a day, respectively, in the morning and at night after chemotherapy, which was carried out for  $\geq 20$  days per month. The recipe of ADD treatment was prescribed by the pharmacy department of Minhang Hospital affiliated to Fudan University, including 30 g Astragalus, 15 g *Radix Pseudostellariae*, 30 g Coix Seed, 10 g *Atractylodes*, 10 g *Poria Cocos*, 10 g Thunberg Fritillary Bulb, 15 g *Radix Scrophulariae*, 10 g *Radix Ophiopogonis*, 15 g *Ligustrum*

lucidum, 15 g Nightshade, 30 g Hedyotis Diffusa, 30 g Scutellariae Barbatae, 10 g Edulis, and 6 g Licorice. About 5 mL peripheral venous blood was taken from each subject, respectively, before and after the treatments. The blood samples were centrifuged at 8,200 r/min for 10 minutes, and the resultants were reserved to determine hsa\_circ\_0001982, miR-206, and miR-613 levels using real-time polymerase chain reaction (PCR), as described below.

## Follow-Up of TNBC Patients

The TNBC patients were followed up via telephone call or record query from the date of pathological diagnosis until November 2020. Nobody withdrew from this program half-way.

## Cell Culture

The MDA-MB-231/ADR cell line, BT-549/ADR cell line, and MDA-MB-549/ADR cell line were produced by separately stimulating the MDA-MB-231 cell line, BT-549 cell line, and MDA-MB-549 cell line, all purchased from the cell bank of the Chinese Academy of Sciences (Shanghai, China), with increasing concentrations of adriamycin (ADM) (Shenzhen Main Luck Pharmaceuticals Inc, China). After incubation by 1.0 µg/mL ADM-inclusive RPMI 1640 medium, MDA-MB-231/ADR, BT-549/ADR, and MDA-MB-549/ADR cell lines were cultivated in ADM-free RPMI medium for about 2 weeks. The MDA-MB-231 cell line was cultured in RPMI 1640 medium (Gibco, USA) blended by 10% fetal bovine serum (FBS) and 100 µg/mL penicillin-streptomycin. All the cell lines were cultivated under circumstances of 37°C, 5% CO<sub>2</sub>, and saturated humidity, and cells at the logarithmic growth phase were collected.

## Cell Treatment and Cell Transfection

The MDA-MB-231/ADR cell line, BT-549/ADR cell line, and MDA-MB-549/ADR cell line that grew to 90% confluence was treated by astragaloside IV at the final concentration of 40 µg/mL (National Institute for Control of Pharmaceutical and Biological Products, China). Furthermore, the MDA-MB-231/ADR cell line was transfected by si-hsa\_circ\_0001982 (5'-CCCUCUAAAUAAGGAAUAA-3'), si-NC (5'-UUCUCCGAACGUGUCACGU, GenePharma, China), miR-206 mimic/inhibitor (Ribobio, China), miR-613 mimic/inhibitor (Sangon, China), or miR-NC (Sangon) for 48 hours, with the assistance of a Lipo2000<sup>TM</sup> transfection kit (Invitrogen, USA)

## CCK8 Assay to Determine Cell Proliferation

The MDA-MB-231/ADR cell line, BT-549/ADR cell line, and MDA-MB-549/ADR cell line at the density of  $5 \times 10^3$ /well were inoculated into 96-well plates for 2 days, and then 10 µL CCK-8 reagent (DOJINDO, Japan) was dropped into each well. Subsequently, MDA-MB-231/ADR, BT-549/ADR and MDA-MB-549/ADR cell lines were incubated at 37°C for 2 hours, and absorbance (A) of each well at 450 nm was examined using a microplate reader (model: multiskan Mk3, Thermo Lab Systems, Finland).

## Transwell Assay to Assess Cell Migration and Cell Invasion

### Cell Migration

The MDA-MB-231/ADR cells, BT-549/ADR cells, and MDA-MB-549/ADR cells, digested by 0.25% trypsin to the concentration of  $2 \times 10^5$ /mL, were inoculated into the upper layer of a Transwell chamber (Corning, USA), and 500 µL RPMI 1640 medium that included 20% FBS was added to the lower layer of the Transwell chamber. After incubation in 5% CO<sub>2</sub> at 37°C for 24 hours, culture medium in the upper Transwell chamber was removed, and cells were fixated by 4% paraformaldehyde for 15 minutes and then stained by 1% crystal violet for 15 minutes at room temperature. Five fields of views were randomly photographed under an inverted microscope (Olympus, Japan).

### Cell Invasion

Matrigel (Corning, USA) stored at -20°C was placed within a 4-°C refrigerator 1 day before the experiment. Then Matrigel in the liquid state was diluted by precooled serum-free RPMI 1640 medium at the ratio of 1: 8 (v/v), and 50 µL Matrigel was paved onto the upper Transwell chamber at 37°C for 5 hours. Other procedures were identical with steps detailed in the cell migration part.

## MTT Assay to Evaluate MDR of MDA-MB-231/ADR Cell Line

Precisely 100 µL single-cell suspension of MDA-MB-231/ADR cell line was seeded into each well of 96-well plates at the density of  $6 \times 10^4$ /mL. Twenty-four hours later, MDA-MB-231/ADR cells were treated by varying concentrations of gemcitabine (GEM) (Hansoh Pharmaceutical Group, Jiangsu province, China), oxaliplatin (OXA) (Qilu

Pharmaceutical Corporation, Shandong province, China), ADM, paclitaxel (PTX) (Cisen Pharmaceutical Corporation, Shandong province, China), and cisplatin (DDP) (Jiangsu Hansoh Pharmaceutical Group, China). After cultivation in 5% CO<sub>2</sub> for 24 hours, MDA-MB-231/ADR cells were managed by MTT solution (Sigma, USA) at 37°C for 2 hours. Subsequently, supernatants were discarded, and 150 µL dimethyl sulfoxide (DMSO) (Beijing Solarbio, China) was added into each well, the results of which were shaken for 10 minutes to dissolve the deposited crystals. Eventually, absorbance (A) values of each well were measured at 490 nm with a microplate reader (model: 2550, Bio-rad, USA). The inhibition rate (%) of drugs on growth of MDA-MB-231/ADR cells was calculated as per formula of:  $[1 - (A_{\text{Experimental group}} - A_{\text{Blank group}}) / (A_{\text{Control group}} - A_{\text{Blank group}})] \times 100\%$ , and half maximal inhibitory concentration (IC<sub>50</sub>) was calculated through linear regression analysis.

### Glucose Consumption and Lactate Release of MDA-MB-231/ADR Cell Line

Exactly  $7 \times 10^5$  MDA-MB-231/ADR cells under each treatment were cultured within 12-well plates overnight, and they were counted by feat of hemocytometer. Glucose consumption and lactate release of MDA-MB-231/ADR cells were determined and quantified by employing an AU5400 biochemical instrument (Olympus, Japan) and Rxl Max software (Dade-Behring, USA).

### Metabolic Activity of MDA-MB-231/ADR Cell Line

MDA-MB-231/ADR cells were seeded within culture plates of Seahorse XFe96 analyzer (Agilent, USA) overnight. Afterwards, oligomycin, Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), antimycin A/rotenone, and 2-deoxy-D-glucose were successively added to incubate the MDA-MB-231/ADR cells at 37°C for 30 minutes, according to instructions of glycolytic rate assay kit (Seahorse, USA). Extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) were monitored on the Seahorse XFe96 analyzer (Agilent, USA).

### Real-Time PCR

Concentration of total RNAs, isolated from blood samples and cell lines by addition of Trizol reagent (Invitrogen, USA), was measured via a microplate reader (model: imark, Corning, USA). With the usage of PrimeScript kit (TaKaRa, Japan) or Bulge-Loop<sup>TM</sup> miRNA kit (RiboBio,

Guangzhou province, China), RNAs were reversely transcribed into cDNAs, which were then amplified on the PCR platform (model: LightCycler480, Roche, Sweden) in line with specifications of SYBR Premix Ex Taq GC kit (Takara, Japan). Primers of genes ([Supplementary Table 1](#)) were designed and synthesized by Genepharma (Shanghai, China), and their relative levels were drawn abiding by  $2^{-\Delta\Delta CT}$  technique. GAPDH was set as the internal reference of hsa\_circ\_0001982, and expression of miR-206/miR-613 was normalized to that of U6.

### Dual-Luciferase Reporter Gene Assay

Exactly  $5 \times 10^4$  MDA-MB-231/ADR cells were seeded into each well of 24-well plates, until they were grown to 80% confluency. Following steps detailed in the Lipofectamine 2000<sup>TM</sup> transfection kit (Invitrogen, USA), wild-type and mutant-type pGL3-hsa\_circ\_0001982 (Ribobio, China) were, respectively, co-transfected with miR-613 mimic, miR-206 mimic, or miR-NC (Sangon, China) into MDA-MB-231/ADR cells. Forty-eight hours later, firefly luciferase and Renilla luciferase activities of each cell sample were determined by virtue of the Dual luciferase reporter assay system (RiboBio, China), and luciferase activity was equivalent to firefly luciferase divided by renilla luciferase activity.

### Statistical Analysis

All statistical analyses were carried out using SPSS ver17.0 software (SPSS, USA). Measurement data, revealed as mean±standard deviation (SD), were analyzed using student's *t*-test or single-factor analysis of variance (ANOVA), and the count data were compared by chi-square test. It was statistically significant in the event of *P* (two-sided)<0.05.

## Results

### Astragalus Detoxification Decoction (ADD) Improved TNBC Prognosis After Chemotherapy and Altered Serum Levels of hsa\_circ\_0001982, miR-206, and miR-613

TNBC patients of the ADD treatment group and non-ADD treatment group were matched regarding mean age, menstrual status, family history, pathological type, clinical staging, tumor diameter, lymph node metastasis in axillary fossa, surgery form, and disease course (all *P*>0.05)

([Supplementary Table 2](#)). However, TNBC patients who received ADD adjuvant therapy were associated with higher odds of TNBC relapse, including local recurrence (n=2) and distant metastasis (n=5), than patients without ADD treatment (local recurrence: n=8; distant metastasis: n=17) ( $P<0.05$ ) ([Supplementary Figure 1A](#)).

Furthermore, hsa\_circ\_0001982 level was increased ([Supplementary Figure 1B](#)), while levels of miR-206 ([Supplementary Figure 1C](#)) and miR-613 ([Supplementary Figure 1D](#)) were decreased in pre-chemotherapy serum of TNBC patients as compared with serum of healthy volunteers ( $P<0.05$ ). Besides, hsa\_circ\_0001982 level fell significantly, and miR-206/miR-613 level declined markedly in post-chemotherapy serum of TNBC patients, when compared with their pre-chemotherapy serum ( $P<0.05$ ). And TNBC patients who accepted ADD adjuvant treatment revealed a low hsa\_circ\_0001982 level and high miR-206/miR-613 level in their serum as compared with TNBC patients who refused to intake ADD ( $P<0.05$ ). Moreover, we observed that hsa\_circ\_0001982 level was negatively correlated with miR-206/miR-613 level among pre-chemotherapy and post-chemotherapy, including with and without ADD treatment, serum samples of TNBC patients, respectively ( $P<0.05$ ) ([Supplementary Figure 1E](#)).

### Astragaloside IV Impaired Malignant Activity and Affected hsa\_circ\_0001982-miR-206/miR-613 Axis of Drug-Resistant TNBC Cell Lines


Proliferation ([Figure 1A](#)), migration ([Figure 1B](#)), and invasion ([Figure 1C](#)) of the BT-549/ADR cell line, MDA-MB-468/ADR cell line, and MDA-MB-231/ADR cell line were demotivated after astragaloside IV treatment (all  $P<0.05$ ). Moreover, hsa\_circ\_0001982 expression was down-regulated, and miR-206/miR-613 expression was up-regulated in the BT-549 cell line, MDA-MB-468 cell line, and MDA-MB-231 cell line, respectively, compared with the BT-549/ADR cell line, MDA-MB-468/ADR cell line, and MDA-MB-231/ADR cell line (all  $P<0.05$ ) ([Figure 1D](#)). Exposure to astragaloside IV depressed hsa\_circ\_0001982 expression and heightened miR-206/miR-613 expression most significantly in the MDA-MB-231/ADR cell line ( $P<0.05$ ), as relative to the BT-549/ADR cell line and MDA-MB-468/ADR cell line ([Figure 1D](#)).

### Astragaloside IV Attenuated MDR and Glycolysis of MDA-MB-231/ADR Cell Line

MDA-MB-231/ADR cells were strongly resistant to lethal effects of GEM ( $IC_{50}=250.78 \mu\text{mol/L}$ ), ADM ( $IC_{50}=22.71 \mu\text{g/mL}$ ), OXA ( $IC_{50}=8.39 \mu\text{mol/L}$ ), and DDP ( $IC_{50}=23.56 \text{ mg/L}$ ), when compared with the MDA-MB-231 cell line (GEM:  $IC_{50}=13.86 \mu\text{mol/L}$ ; ADM:  $IC_{50}=0.55 \mu\text{g/mL}$ ; OXA:  $IC_{50}=1.69 \mu\text{mol/L}$ ; DDP:  $IC_{50}=5.53 \text{ mg/L}$ ) ([Figure 2A](#)). However, astragaloside IV treatment made the MDA-MB-231/ADR cell line more vulnerable to the harms induced by GEM ( $IC_{50}=45.45 \mu\text{mol/L}$ ), ADM ( $IC_{50}=2.89 \mu\text{g/mL}$ ), OXA ( $IC_{50}=3.49 \mu\text{mol/L}$ ), and DDP ( $IC_{50}=10.56 \mu\text{g/mL}$ ) ([Figure 2A](#)). Furthermore, MDA-MB-231/ADR cells exposed to astragaloside IV consumed less glucose ([Figure 2B](#)) and produced smaller amounts of lactate ([Figure 2C](#)) than untreated MDA-MB-231/ADR cells (both  $P<0.05$ ). ECAR ([Figure 2D](#)) and OCR ([Figure 2E](#)) of MDA-MB-231/ADR cells were also reduced after astragaloside IV treatment (both  $P<0.05$ ), which indicated that astragaloside IV enabled metabolic transformation of the MDA-MB-231/ADR cell line from glycolysis-dependent to predominantly aerobic.

### MiR-206 and miR-613 Were Sponged and Down-Regulated by hsa\_circ\_0001982 in the MDA-MB-231/ADR Cell Line

MiR-206 expression was fortified by miR-206 mimic and was dwindled by miR-206 inhibitor ( $P<0.05$ ) ([Figure 3A](#)), whereas miR-613 mimic and inhibitor, respectively, fostered and abated expression of miR-613 ( $P<0.05$ ) ([Figure 3B](#)). Luciferase activity of MDA-MB-231/ADR cells, measured by dual-luciferase reporter gene assay, was declined in the pGL3-hsa\_circ\_0001982 Wt+miR-206 mimic group, as relative to the pGL3-hsa\_circ\_0001982 Mut+miR-206 mimic group and pGL3-hsa\_circ\_0001982 Wt+miR-NC group ( $P<0.05$ ) ([Figure 3C](#)). Analogously, luciferase activity of the MDA-MB-231/ADR cell line was reduced by co-treatment of pGL3-hsa\_circ\_0001982 Wt and miR-613 mimic, when compared with the pGL3-hsa\_circ\_0001982 Mut+miR-613 mimic group and pGL3-hsa\_circ\_0001982 Wt+miR-NC group ( $P<0.05$ ) ([Figure 3D](#)). Furthermore, hsa\_circ\_0001982 expression




**Figure 1** Proliferation (A), migration (B), invasion (C), and expressions of hsa\_circ\_0001982/miR-206/miR-613 axis (D) were determined in the BT-549/ADR cell line, MDA-MB-468/ADR cell line, and MDA-MB-231/ADR cell line after astragaloside IV treatment. (A–C) \* $P < 0.05$  in comparison to control group. (D) \* $P < 0.05$ .

in the MDA-MB-231/ADR cell line was pronouncedly lowered by si-hsa\_circ\_0001982 as relative to the si-NC group (all  $P < 0.05$ ) (Figure 3E). And expressions of miR-206 and miR-613 were notably lessened after si-hsa\_circ\_0001982 transfection, when compared with the si-NC group (all  $P < 0.05$ ) (Figure 3F).

## Hsa\_circ\_0001982-miR-206/miR-613 Axis Manipulated MDR, Proliferation, Migration, Invasion, and Glycolysis of the MDA-MB-231/ADR Cell Line

Propelled by si-hsa\_circ\_0001982, the MDA-MB-231/ADR cell line became sensitive against GEM



**Figure 2** Astragaloside IV relieved multi-drug resistance and glycolysis of the MDA-MB-231/ADR cell line. **(A)** Effect of astragaloside IV on gemcitabine-, adriamycin-, oxaliplatin-, and cisplatin-resistances of the MDA-MB-231/ADR cell line. \* $P < 0.05$  in comparison to NC group. **(B–E)** Glucose uptake **(B)**, lactate production **(C)**, extracellular acidification rate (ECAR) **(D)**, and oxygen consumption rate (OCR) **(E)** of the MDA-MB-231/ADR cell line were evaluated after exposure to astragaloside IV. \* $P < 0.05$  in comparison to the NC group.


(IC<sub>50</sub>=16.23 μmol/L), ADM (IC<sub>50</sub>=1.12 μg/mL), OXA (IC<sub>50</sub>=1.38 μmol/L), and DDP (IC<sub>50</sub>=7.86 μg/mL), as compared with the untreated MDA-MB-231/ADR cell line ( $P < 0.05$ ) (Figure 4A). Additional transfection of the miR-206 inhibitor (ie, si-hsa\_circ\_0001982+miR-206 inhibitor group) made the si-hsa\_circ\_0001982-transfected MDA-MB-231/ADR cell line more susceptible to injuries triggered by GEM (IC<sub>50</sub>=190.94 μmol/L), ADM (IC<sub>50</sub>=22.71 μg/mL), OXA (IC<sub>50</sub>=8.39 μmol/L), and DDP (IC<sub>50</sub>=23.56 μg/mL) ( $P < 0.05$ ). Similarly, chemo-tolerance of the si-hsa\_circ\_0001982-transfected MDA-MB-231/ADR cell line was enhanced by miR-613 inhibitor, regardless of GEM (IC<sub>50</sub>=52.22 μmol/L), ADM (IC<sub>50</sub>=9.31 μg/mL), OXA (IC<sub>50</sub>=3.44 μmol/L), and DDP (IC<sub>50</sub>=13.02 mg/L) (all  $P < 0.05$ ). Furthermore, the MDA-MB-231/ADR cell line was restrained from migrating (Figure 4B), invading (Figure 4C), and proliferating (Figure 4D) after si-hsa\_circ\_0001982 transfection (all  $P < 0.05$ ), yet the miR-206/miR-613 inhibitor, to some extent, debilitated the contribution of si-hsa\_circ\_0001982 to these activities of the MDA-MB-231/ADR cell line (all  $P < 0.05$ ).

Moreover, both glucose uptake (Figure 4E) and lactate release (Figure 4F) were decreased in MDA-MB-231/ADR cells after silencing of si-hsa\_circ\_0001982 (all  $P < 0.05$ ). Nevertheless, MDA-MB-231/ADR cells in the si-


hsa\_circ\_0001982+miR-206/613 inhibitor group absorbed more glucose and secreted more lactate than cells of the si-hsa\_circ\_0001982 group (all  $P < 0.05$ ). Silencing of hsa\_circ\_0001982 also significantly decreased ECAR (Figure 4G) and OCR (Figure 4H) of MDA-MB-231/ADR cells as compared with the si-NC group (all  $P < 0.05$ ), while ECAR and OCR of MDA-MB-231/ADR cells were raised in the si-hsa\_circ\_0001982+miR-206/613 inhibitor group as relative to the si-hsa\_circ\_0001982 group (all  $P < 0.05$ ). These results suggested that MDA-MB-231/ADR cells in the si-hsa\_circ\_0001982 group were more reliant on aerobic metabolism than cells in the si-NC group, and their metabolism could be reversed to primarily glycolytic after extra transfection of the miR-206/613 inhibitor.

## MiR-206 and miR-613 Participated in the Effects of Astragaloside IV on MDR, Proliferation, Migration, Invasion, and Glycolysis of the MDA-MB-231/ADR Cell Line

Transfection of the miR-206 inhibitor or miR-613 inhibitor partly blocked the alleviating effects of astragaloside IV on MDA-MB-231/ADR cells' resistance to GEM (IC<sub>50</sub>=75.01 μmol/L; IC<sub>50</sub>=130.11 μmol/L), ADM (IC<sub>50</sub>=6.82 μg/mL; IC<sub>50</sub>=7.68 μg/mL), OXA (IC<sub>50</sub>=7.20 μmol/L; IC<sub>50</sub>=4.43



**Figure 3** The sponging relationship between hsa\_circ\_0001982 and miR-206/miR-613 in the MDA-MB-231/ADR cell line. \* $P < 0.05$ . (A and B) Expressions of miR-206 (A) and miR-613 (B) were, respectively, detected in MDA-MB-231/ADR cells after separate transfection of miR-206/miR-613 mimic and inhibitor. \* $P < 0.05$ . (C) The target sites of hsa\_circ\_0001982 and miR-206 were displayed, and luciferase activity of MDA-MB-231/ADR cells was reduced in the pGL3-hsa\_circ\_0001982 Wt+miR-206 mimic group as compared with the pGL3-hsa\_circ\_0001982 Mut+miR-206 mimic group and the pGL3-hsa\_circ\_0001982 Wt+miR-NC group. \* $P < 0.05$ . (D) MiR-613 was sponged by hsa\_circ\_0001982 in certain sites, and luciferase activity of MDA-MB-231/ADR cells was decreased in the pGL3-hsa\_circ\_0001982 Wt+miR-613 mimic group as compared with the pGL3-hsa\_circ\_0001982 Mut+miR-613 mimic group and pGL3-hsa\_circ\_0001982 Wt+miR-NC group. \* $P < 0.05$ . (E) Hsa\_circ\_0001982 expression in MDA-MB-231/ADR cells was measured after silencing of hsa\_circ\_0001982. \* $P < 0.05$ . (F) MiR-206/miR-613 expression in MDA-MB-231/ADR cells was altered after silencing of hsa\_circ\_0001982. \* $P < 0.05$ .



**Figure 4** Hsa\_circ\_0001982-miR-206/miR-613 axis manipulated multi-drug resistance (A), migration (B), invasion (C), proliferation (D), and glycolysis, indicated by glucose uptake (E), lactate production (F), extracellular acidification rate (ECAR) (G), and oxygen consumption rate (OCR) (H), of MDA-MB-231/ADR cell line. (A–C) \* $P < 0.05$ . (D) \* $P < 0.05$  in comparison to the NC group; # $P < 0.05$  in comparison to the si-hsa\_circ\_0001982 transfection group. (E and F) \* $P < 0.05$ . (G and H) \* $P < 0.05$  in comparison to the NC group; # $P < 0.05$  in comparison to the si-hsa\_circ\_0001982 transfection group.

**Abbreviations:** GEM, gemcitabine; ADM, adriamycin; OXA, oxaliplatin; DDP, cisplatin.

μmol/L), and DDP ( $IC_{50}$ =17.15 μg/mL;  $IC_{50}$ =13.42 μg/mL) (all  $P<0.05$ ) (Figure 5A). Extra transfection of the miR-206 inhibitor or miR-613 inhibitor (ie astragaloside IV+miR-206 inhibitor/miR-613 inhibitor group) also reinforced migration (Figure 5B) and invasion (Figure 5C) of MDA-MB-231/ADR cells in comparison to astragaloside IV treatment alone (all  $P<0.05$ ). Moreover, transfection of the miR-206 inhibitor or miR-613 inhibitor led to larger ECAR (Figure 5G) and OCR (Figure 5H) in astragaloside IV-exposed MDA-MB-231/ADR cells (all  $P<0.05$ ), insinuating that the miR-206/613 inhibitor restored astragaloside IV-decreased glycolysis of MDA-MB-231/ADR cells.

## Discussion


TNBC, characterized by large tumor size and nest-shaped blood vessels, usually engendered the poorest prognosis among all BC subtypes. Allowing for that emergence of MDR usually gave rise to treatment failure among TNBC patients, clarifying its underlying pathogenesis was indispensable to perfecting TNBC treatment.

In this investigation, we noticed that intake of ADD was conducive to improving TNBC prognosis after chemotherapy (Supplementary Figure 1A), which implied that components of ADD, such as astragaloside IV, might be effective in attenuating fallouts triggered by chemotherapy (eg, MDR). Actually, the anti-tumor mechanism of astragaloside IV has been documented massively, for example, astragaloside IV not only blocked MDR of 5-fluorouracil (5-Fu)-resistant liver cancer (ie, Bel-7402/FU) cell line,<sup>19</sup> but also slowed down metastasis of lung cancer cells (eg, A540 cell line).<sup>20</sup> In this study we newly demonstrated that astragaloside IV was able to suppress MDR (Figure 2A), malignant activities (Figure 1A–D), and glycolysis (Figure 2B–E) of the MDA-MB-231/ADR cell line. Furthermore, astragaloside IV was reported to antagonize neoplastic progression by modifying downstream pathways, such as PKC-α-ERK1/2-NF-κB signaling<sup>20</sup> and Rac1/MAPK signaling.<sup>21</sup> Extending knowledge of this part, here we identified that the hsa\_circ\_0001982-miR-206/miR-613 axis was possibly subjected to modulation of astragaloside IV in TNBC (Figure 1D).

Up to date, a variety of circRNAs have been validated to promote or impede BC progression, for instance, circGFRA1, a biomarker of poor TNBC prognosis, could spur TNBC exacerbation through sponging miR-34a.<sup>22</sup> On top of that, hsa\_circ\_0001982 focused on here was indicative of poor survival among TNBC patients,<sup>22</sup> and this investigation proposed a novel perspective that


astragaloside IV might restrain TNBC aggravation by down-regulating hsa\_circ\_0001982 (Figure 1D). What's more, plenty of investigations have stressed that circRNAs restored MDR of tumor cells probably by depressing their capabilities in proliferating and metastasizing. In particular, tamoxifen-resistance, migration, and invasion of hormone receptor (HR)-positive BC cells were weakened by hsa\_circ\_0025202,<sup>23</sup> whereas silencing of hsa\_circ\_0001275 reversed cisplatin-tolerance and blocked migration of esophageal cancer cells.<sup>24</sup> Following this logic, it might be through debilitating proliferation, migration, and invasion that si-hsa\_circ\_0001982 undermined MDR of the drug-resistant TNBC cell line (Figure 4). Moreover, glycolysis was required for tumor cells to acquire energy and intermediate metabolites, so that cancer cells progressed quite swiftly.<sup>25</sup> It was documented that in-vivo and in-vitro application of 3-bromopyruvate, an inhibitor of glycolysis, could effectively decelerate BC progression,<sup>26</sup> insinuating that manipulating glycolysis of tumor cells was pivotal to fight against neoplasms.<sup>27</sup> Interestingly, this investigation revealed that silencing of hsa\_circ\_0001982 was able to impair the glycolytic potential of MDR-featured TNBC cells (Figure 4E–H), which emphasized that glycolysis, apart from proliferation, migration, and invasion, was also involved in hsa\_circ\_0001982-modulated MDR of TNBC.

Additionally, miR-206 and miR-613 were sponged by hsa\_circ\_0001982 in the MDA-MB-231/ADR cell line (Figure 3), and they interfered with the effect of hsa\_circ\_0001982 on proliferation, migration, invasion, MDR, and glycolysis of drug-resistant TNBC cells (Figure 4), which was a highlight of this study. Former reports exposed that miR-206 and miR-613 both prevented against neoplastic development,<sup>28,29</sup> and they served to restrain chemoresistance of cancer cells. Specifically, miR-206 enhanced 5-Fu-sensitivity of ovarian cancer cells<sup>30</sup> and facilitated euthyrox-sensitivity of papillary thyroid carcinoma cells,<sup>31</sup> whereas miR-613 rescued cisplatin-sensitivity of gastric cancer cells.<sup>32,33</sup> Not only that, miR-206 and miR-613 also impaired the capability of tumor cells, such as gastric cancer and BC, in performing glycolysis,<sup>34,35</sup> which all underlined the protective role of miR-206/miR-613 in hindering TNBC progression. Apart from si-hsa\_circ\_0001982, miR-206 and miR-613 also modified impacts of astragaloside IV on TNBC glycolysis and development (Figure 5), which collectively demonstrated that miR-206 and miR-613 were vital players in



**Figure 5** MiR-206 and miR-613 restored effects of astragaloside IV on multi-drug resistance (A), migration (B), invasion (C), proliferation (D), glucose uptake (E), lactate production (F), extracellular acidification rate (ECAR) (G), and oxygen consumption rate (OCR) (H) of the MDA-MB-231/ADR cell line. (A) \* $P < 0.05$  in comparison to the NC group; # $P < 0.05$  in comparison to the si-hsa\_circ\_0001982 transfection group. (B and C) \* $P < 0.05$ . (D) \* $P < 0.05$  in comparison to the NC group; # $P < 0.05$  in comparison to the si-hsa\_circ\_0001982 transfection group. (E and F) \* $P < 0.05$ . (G and H) \* $P < 0.05$  in comparison to the NC group; # $P < 0.05$  in comparison to the si-hsa\_circ\_0001982 transfection group.

**Abbreviations:** GEM, gemcitabine; ADM, adriamycin; OXA, oxaliplatin; DDP, cisplatin.



**Figure 6** Astragaloside IV down-regulated hsa\_circ\_0001982, thereby disordering binding between hsa\_circ\_0001982 and miR-206/miR-613. Consequently, multi-drug resistance, glycolysis, migration, and invasion of the drug-resistant TNBC cell line (ie, MDA-MB-231/ADR) were weakened.

astragaloside IV/hsa\_circ\_0001982-regulated TNBC progression.

In conclusion, astragaloside IV ameliorated MDR, glycolysis, migration, and invasion of the drug-resistant TNBC cell line by obstructing the hsa\_circ\_0001982-miR-206/miR-613 signaling axis (Figure 6), providing molecular evidence that ADD treatment might be beneficial to TNBC prognosis after chemotherapy. Nonetheless, there were some shortcomings in the experimental design. Firstly, treatment efficacy of astragaloside IV on other BC subtypes was not explored. Secondly, whether the results of this study were applicable to populations of different scales and ethnicities was uncertain. Thirdly, we hardly emulated astragaloside IV treatment in animal models, so that the in-vivo impact of astragaloside IV on TNBC was not explored.

## Acknowledgments and Fundings

This work was supported by grants from the National Natural Science Foundation of China (NSFC) (No. 81703881), Minhang District Science and Technology Commission Project(2019MHZ030)and High Level Key Specialist Doctors under the Medical Teaching Research Collaborative Health Service System in Minhang District (No. 2020MZYS02).

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. *Nature*. 2012;490(7418):61–70. doi:10.1038/nature11412
2. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. *N Engl J Med*. 2010;363:1938–1948. doi:10.1056/NEJMra1001389
3. Guestini F, McNamara KM, Ishida T, Sasano H. Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers identification. *Expert Opin Ther Targets*. 2016;20:705–720. doi:10.1517/14728222.2016.1125469
4. Nedeljkovic M, Damjanovic A. Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge. *Cells*. 2019;8:957. doi:10.3390/cells8090957
5. Meng S, Zhou H, Feng Z, et al. CircRNA: functions and properties of a novel potential biomarker for cancer. *Mol Cancer*. 2017;16:94. doi:10.1186/s12943-017-0663-2
6. Li Z, Chen Z, Hu G, Jiang Y. Roles of circular RNA in breast cancer: present and future. *Am J Transl Res*. 2019;11:3945–3954.
7. Li H, Yao G, Feng B, Lu X, Fan Y. Circ\_0056618 and CXCR4 act as competing endogenous in gastric cancer by regulating miR-206. *J Cell Biochem*. 2018;119:9543–9551. doi:10.1002/jcb.27271
8. Tang YY, Zhao P, Zou TN, et al. Circular RNA hsa\_circ\_0001982 promotes breast cancer cell carcinogenesis through decreasing miR-143. *DNA Cell Biol*. 2017;36:901–908. doi:10.1089/dna.2017.3862
9. Glazar P, Papavasileiou P, Rajewsky N. circBase: a database for circular RNAs. *RNA*. 2014;20:1666–1670. doi:10.1261/rna.043687.113
10. Dori M, Biccato S. Integration of bioinformatic predictions and experimental data to identify circRNA-miRNA associations. *Genes*. 2019;10(9):642. doi:10.3390/genes10090642
11. Li Y, Zheng F, Xiao X, et al. CircHIPK3 sponges miR-558 to suppress heparanase expression in bladder cancer cells. *EMBO Rep*. 2017;18:1646–1659. doi:10.15252/embr.201643581
12. Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. *Nucleic Acids Res*. 2014;42:D92–97. doi:10.1093/nar/gkt1248
13. Sasaki A, Tsunoda Y, Tsuji M, et al. Decreased miR-206 expression in BRCA1 wild-type triple-negative breast cancer cells after concomitant treatment with gemcitabine and a Poly(ADP-ribose) polymerase-1 inhibitor. *Anticancer Res*. 2014;34:4893–4897.
14. Xiong H, Yan T, Zhang W, et al. miR-613 inhibits cell migration and invasion by downregulating Daam1 in triple-negative breast cancer. *Cell Signal*. 2018;44:33–42. doi:10.1016/j.cellsig.2018.01.013
15. Wang B, Guo C, Liu Y, et al. Novel nano-pomegranates based on astragalus polysaccharides for targeting ERalpha-positive breast cancer and multidrug resistance. *Drug Deliv*. 2020;27:607–621. doi:10.1080/10717544.2020.1754529
16. Li W, Hu X, Wang S, et al. Characterization and anti-tumor bioactivity of astragalus polysaccharides by immunomodulation. *Int J Biol Macromol*. 2020;145:985–997. doi:10.1016/j.ijbiomac.2019.09.189
17. Kang JX, Liu J, Wang J, He C, Li FP. The extract of huanglian, a medicinal herb, induces cell growth arrest and apoptosis by upregulation of interferon-beta and TNF-alpha in human breast cancer cells. *Carcinogenesis*. 2005;26:1934–1939. doi:10.1093/carcin/bgi154
18. Lau FY, Chui CH, Gambari R, et al. Antiproliferative and apoptosis-inducing activity of Brucea javanica extract on human carcinoma cells. *Int J Mol Med*. 2005;16:1157–1162.

19. Wang PP, Xu DJ, Huang C, Wang WP, Xu WK. Astragaloside reduces the expression level of P-glycoprotein in multidrug-resistant human hepatic cancer cell lines. *Mol Med Rep.* **2014**;9:2131–2137. doi:10.3892/mmr.2014.2074
20. Cheng X, Gu J, Zhang M, et al. Astragaloside IV inhibits migration and invasion in human lung cancer A549 cells via regulating PKC- $\alpha$ -ERK1/2-NF- $\kappa$ B pathway. *Int Immunopharmacol.* **2014**;23:304–313. doi:10.1016/j.intimp.2014.08.027
21. Jiang K, Lu Q, Li Q, et al. Astragaloside IV inhibits breast cancer cell invasion by suppressing Vav3 mediated Rac1/MAPK signaling. *Int Immunopharmacol.* **2017**;42:195–202. doi:10.1016/j.intimp.2016.10.001
22. He R, Liu P, Xie X, et al. circGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a. *J Exp Clin Cancer Res.* **2017**;36:145. doi:10.1186/s13046-017-0614-1
23. Sang Y, Chen B, Song X, et al. circRNA\_0025202 regulates tamoxifen sensitivity and tumor progression via regulating the miR-182-5p/FOXO3a axis in breast cancer. *Mol Ther.* **2019**;27:1638–1652. doi:10.1016/j.ymthe.2019.05.011
24. Zou FW, Yang SZ, Li WY, et al. circRNA\_001275 upregulates Wnt7a expression by competitively sponging miR3703p to promote cisplatin resistance in esophageal cancer. *Int J Oncol.* **2020**;57:151–160. doi:10.3892/ijo.2020.5137
25. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell.* **2011**;144:646–674. doi:10.1016/j.cell.2011.02.013
26. Liu Z, Sun Y, Hong H, et al. 3-bromopyruvate enhanced daunorubicin-induced cytotoxicity involved in monocarboxylate transporter 1 in breast cancer cells. *Am J Cancer Res.* **2015**;5:2673–2685.
27. Jia L, Huang S, Yin X, et al. Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction. *Life Sci.* **2018**;208:123–130. doi:10.1016/j.lfs.2018.07.027
28. Mei J, Xu R, Hao L, Zhang Y. MicroRNA-613: a novel tumor suppressor in human cancers. *Biomed Pharmacother.* **2020**;123:109799. doi:10.1016/j.biopha.2019.109799
29. Zhou Y, Wang M, Tong Y, et al. miR-206 promotes cancer progression by targeting full-length neurokinin-1 receptor in breast cancer. *Technol Cancer Res Treat.* **2019**;18:1533033819875168. doi:10.1177/1533033819875168
30. Ling C, Liu S, Wang Y, Zhang FC, Du Y. [Role of miR-206/CDK4 in modulating the growth and chemotherapy sensitivity of ovarian cancer cells]. *Nan Fang Yi Ke Da Xue Xue Bao.* **2017**;37:393–397. [Chinese].
31. Liu F, Yin R, Chen X, et al. Over-expression of miR-206 decreases the Euthyrox-resistance by targeting MAP4K3 in papillary thyroid carcinoma. *Biomed Pharmacother.* **2019**;114:108605. doi:10.1016/j.biopha.2019.108605
32. Xue M, Li G, Sun P, et al. MicroRNA-613 induces the sensitivity of gastric cancer cells to cisplatin through targeting SOX9 expression. *Am J Transl Res.* **2019**;11:885–894.
33. Wang X, Zhao Y, Qian H, et al. The miR-101/RUNX1 feedback regulatory loop modulates chemo-sensitivity and invasion in human lung cancer. *Int J Clin Exp Med.* **2015**;8:15030–15042.
34. Liu H, Chen K, Wang L, et al. miR-613 inhibits Warburg effect in gastric cancer by targeting PFKFB2. *Biochem Biophys Res Commun.* **2019**;515:37–43. doi:10.1016/j.bbrc.2019.05.001
35. Ge X, Lyu P, Cao Z, et al. Overexpression of miR-206 suppresses glycolysis, proliferation and migration in breast cancer cells via PFKFB3 targeting. *Biochem Biophys Res Commun.* **2015**;463:1115–1121. doi:10.1016/j.bbrc.2015.06.068

## Cancer Management and Research

Dovepress

### Publish your work in this journal

Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/cancer-management-and-research-journal>